-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On December 15, the clinical trial application of the recombinant 15-valent human papillomavirus (HPV) vaccine (Escherichia coli) jointly developed by Beijing Kangleweishi and Liaoning Chengda Biotechnology Co.
HPV infection can cause diseases of the human reproductive system
In January 2019, Kangle Guardian and Chengda Biotechnology signed a cooperation agreement to jointly develop and restructure 15-price HPV (6/11/16/18/31/33/35/39/45/51/52/56/58/59/ Type 68) vaccine
At present, a total of 4 HPV vaccines have been approved for marketing in China, namely Merck’s Jiadaxiu (4 price), Jiadaxiu 9 (9 price), GlaxoSmithKline’s Cirix (2 price) and Wantai Biotech’s Xin Canning (2 price)
In terms of research products, Zerun Bio's bivalent HPV (type 16/18) vaccine is currently in the stage of applying for the market, and has obtained the priority review qualification of NMPA
In addition to the clinical 15-valent HPV vaccine, the recombinant trivalent HPV (16/18/58) vaccine (E.